Abstract Number: 1355 • 2013 ACR/ARHP Annual Meeting
Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of Methotrexate
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of RA, psoriasis, and psoriatic arthritis. Subcutaneously administered MTX is well absorbed and appears to overcome…Abstract Number: 1337 • 2013 ACR/ARHP Annual Meeting
Nearly Pain Free Self-Administration Of Methotrexate Using An Investigational Auto-Injector: Results Of a Phase-2 Clinical Trial In Rheumatoid Arthritis Patients With Mild-To-Severe Functional Limitations
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…Abstract Number: 1338 • 2013 ACR/ARHP Annual Meeting
Time To Institution Of Disease Modifying Anti-Rheumatic Drugs In Australian Patients With Early Rheumatoid Arthritis
Background/Purpose: Early introduction of disease-modifying anti-rheumatic drugs (DMARDs) has been shown to reduce joint destruction and long-term disability in rheumatoid arthritis (RA). Substantial and irreversible…Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier
Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…Abstract Number: 1340 • 2013 ACR/ARHP Annual Meeting
Functional Disability and Quality Of Life Are More Likely Improved In Patients With Rheumatoid Arthritis Who Achieved The New ACR/EULAR Remission Criteria Compared To DAS28 Remission In Daily Practice
Background/Purpose: The new ACR/EULAR remission criteria were proposed to predict favorable outcome in patients with rheumatoid arthritis (RA). To evaluate the functional disability and quality…Abstract Number: 1341 • 2013 ACR/ARHP Annual Meeting
Significantly Less Glucocorticoids and Better Patient-Reported Outcomes In Women With Early Inflammatory Arthritis Using Oral Contraceptives Compared To Never Users
Background/Purpose: Data on the effects of oral contraceptives (OC) on the course of inflammatory arthritis (IA) are controversial. However, a recent analysis of data from…Abstract Number: 1342 • 2013 ACR/ARHP Annual Meeting
Prognosis In Espoir Rheumatoid Arthritis Cohort At 24 Months According To Remission Status At 12 Months: No Differences In Radiographic Scores According To Prior Remission Status, But Significant Differences In HAQ Scores, Highest For Boolean and RAPID3RJ1 Criteria
Background/Purpose: Different criteria for remission in rheumatoid arthritis (RA) have been developed from a Core Data Set of 7 measures for the DAS28, SDAI, CDAI…Abstract Number: 1343 • 2013 ACR/ARHP Annual Meeting
Are There Differences Between Young and Older Onset Early Rheumatoid Arthritis and Does This Impact Outcomes? An Analysis From The Canadian Early Arthritis Cohort
Background/Purpose: To determine the impact of age on disease and remission in early rheumatoid arthritis (ERA). Methods: Data from the Canadian Early Arthritis Cohort (CATCH)…Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…Abstract Number: 1345 • 2013 ACR/ARHP Annual Meeting
Retinal Vascular Calibre – a Novel Biomarker Of Inflammation and Treatment Response In Rheumatoid Arthritis
Background/Purpose: Retinal vascular calibre measurement is a non-invasive tool for assessing systemic and vascular health. Widened retinal venular calibre (RVC) is associated with systemic inflammation,…Abstract Number: 1347 • 2013 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity Score For Rheumatoid Arthritis Predicts Radiographic Damage In The BeSt Study
Background/Purpose: To determine whether a multi-biomarker disease activity (MBDA) score could predict radiographic damage progression in patients with rheumatoid arthritis (RA). Methods: The BeSt study…Abstract Number: 1348 • 2013 ACR/ARHP Annual Meeting
Initial Combination Therapy In Early Rheumatoid Arthritis: Which Patients Benefit?
Background/Purpose: Initial combination therapy has proven to be effective in early rheumatoid arthritis (RA) patients. To determine which patients benefit from initial combination therapy. Methods:…Abstract Number: 1349 • 2013 ACR/ARHP Annual Meeting
High Rate Of Improvement In Serum Matrix Metalloproteinase-3 Levels At 4 Weeks Predict Remission At 52 Weeks In RA Patients With Adalimumab Therapy
Background/Purpose : Serum MMP-3 is a specific inflammatory marker of the synovium in patients with rheumatoid arthritis (RA). Our aim in this study is to…Abstract Number: 1350 • 2013 ACR/ARHP Annual Meeting
Factors Influencing Selection Of Biologic Therapy and Comparative Effectiveness In Patient Reported Outcomes Among Patients With Rheumatoid Arthritis
Background/Purpose: Treatment of rheumatoid arthritis (RA) with biologics is increasingly common. A better understanding of factors that influence the selection of RA therapies and comparative effectiveness…Abstract Number: 1351 • 2013 ACR/ARHP Annual Meeting
A Comparison Of The Clinical Effectiveness Of Treatment Strategies For Active RA Patients : Using a Prospective Biologic Registry (BIOPSY) and an RA Specific Cohort (KORONA)
Background/Purpose: The results from RCTs may not be generalizable to clinical practice because of their inclusion and exclusion criteria. Instead, observational cohorts and registries might…